Myotonic dystrophy type 2: the 2020 update

Giovanni Meola¹,²

¹ Department of Biomedical Sciences for Health, University of Milan, Italy; ² Department of Neurorehabilitation Sciences, Casa di Cura del Policlinico, Milan, Italy

The myotonic dystrophies are the commonest cause of adult-onset muscular dystrophy. Phenotypes of DM1 and DM2 are similar, but there are some important differences, including the presence or absence of congenital form, muscles primarily affected (distal vs proximal), involved muscle fiber types (type 1 vs type 2 fibers), and some associated multisystemic phenotypes. There is currently no cure for the myotonic dystrophies but effective management significantly reduces the morbidity and mortality of patients. For the enormous understanding of the molecular pathogenesis of myotonic dystrophy type 1 and myotonic dystrophy type 2, these diseases are now called "spliceopathies" and are mediated by a primary disorder of RNA rather than proteins. Despite clinical and genetic similarities, myotonic dystrophy type 1 and type 2 are distinct disorders requiring different diagnostic and management strategies. Gene therapy for myotonic dystrophy type 1 and myotonic dystrophy type 2 appears to be very close and the near future is an exciting time for clinicians and patients.

Key words: myotonic dystrophy type 2, DM2, proximal myotonic myopathy, PROMM, DMPK, CNBP

Introduction

The myotonic dystrophies are the more frequent muscle disorders in adulthood. So far 2 distinct entities have been described: myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2).

In this article I review the discovery of the gene, the clinical features, pathogenetic and management of more recently described DM2. All findings related mainly to clinical aspects, pathomolecular mechanisms, new guidelines of management have been updates to 2020.

Discovery of the genes

Myotonic dystrophies represent a group of dominantly inherited, multisystem (eye, heart, brain, endocrine, gastrointestinal tract, uterus, skin) diseases that share the core features of myotonia, muscle weakness, and early onset cataracts (before 50 years of age). The gene defect responsible for myotonic dystrophy described by Steinert on 1908, was discovered in 1992 and was found to be caused by expansion of a CTG repeat in the 3’ untranslated region of myotonic dystrophy protein kinase gene (DMPK), a gene located on chromosome 19q13.3, encoding a protein kinase 1-3. After the discovery of this gene defect, DNA testing revealed a group of patients with dominantly inherited myotonia, proximal more than distal weakness, and cataracts; these patients were previously diagnosed as having myotonic dystrophy of Steinert but lacked the gene defect responsible for this
Myotonic dystrophy type 2: the 2020 update

Biological basis: pathomolecular mechanisms

Myotonic dystrophy type 2 results from an unstable tetranucleotide repeat expansion, CCTG in intron 1 of the nucleic acid-binding protein (CNBP) gene (previously known as zinc finger 9 gene, ZNF9) on chromosome 3q21.8,9 Myotonic dystrophy of Steinert, the classical form of myotonic dystrophy that results from an unstable trinucleotide repeat expansion on chromosome 19q13.3, was termed myotonic dystrophy type 1-DM1. Patients with the clinical picture of myotonic dystrophy type 2, PROMM, or PDM who have positive DNA testing for the unstable tetranucleotide repeat expansion on chromosome 3q21 were classified as having myotonic dystrophy type 2 (DM2). Reliability of DNA testing to establish or to exclude the diagnosis of myotonic dystrophy type 1 is close to 100%.10 However, caution is necessary in the diagnosis of myotonic dystrophy type 2. At present, much more information is available on the natural history of DM1 than DM2, but knowledge of myotonic dystrophy type 2 will increase at a rapid pace over the next several years.

The fact that 2 repeat sequences located in entirely different genes can cause such similar disease features implies a common pathogenic mechanism. The clinical and molecular parallels between myotonic dystrophy type 1 and type 2 strongly suggest that the mutant RNAs containing the repeat expansions that accumulate in the cell nuclei as foci are responsible for the pathological features common to both disorders. It is now clear that the gain-of-function RNA mechanism is the predominant cause of myotonic dystrophy pathogenesis in which the CUG and CCUG repeats alter cellular function of several RNA-binding proteins. It has been demonstrated that mutant CUG and CCUG RNAs are very stable due to a deficiency of RNA helicase p68.22 The expanded CUG and CCUG RNA form hairpins, imperfect double-stranded structures that lead to dysregulation of 2 important RNA-binding proteins: muscleblind like 1 (MBNL1) and CUG-binding protein 1 (CUGBP1), which are antagonist regulators of alternative splicing of various genes.23,24 Data demonstrate that MBNL1-containing foci in myotonic dystrophy type 2 cells also sequester snRNPs and hnRNPs, splicing factors involved in the early phases of transcript processing 25,26, thus strengthening the hypothesis that a general alteration of pre-mRNA posttranscriptional pathway could be at the basis of the multifactorial phenotype of myotonic dystrophy type 2 patients. In myotonic dystrophies, the downregulation of MBNL1, due to its sequestration in mutant RNA foci, and the up-regulation of CUGBP1 result in abnormal expression of embryonic isoforms in adult tissues. The alteration of pre-mRNA processing strengthens the hypothesis of a spliceopathy that leads to an expression of isoforms inadequate for a particular tissue or developmental stage 27,28 In both myotonic dystrophy type 1 and type 2, missplicing of insulin receptor gene (INSR) was associated with insulin resistance. However, Renna and colleagues re-
ported that post-receptor insulin signal transduction via both IRS1-Akt/PKB and Ras-ERK pathway is impaired in myotonic dystrophy skeletal muscle, thus contributing to insulin resistance observable in myotonic dystrophy type 1 and type 2 patients. Moreover, myotonic dystrophy skeletal muscle exhibits a lower expression of the insulin receptor in type 1 fibers, contributing to the defective activation of the insulin pathway. It is now clear that the molecular pathomechanism of myotonic dystrophies is more complex than actually suggested.

miRNAs are small, noncoding RNA modulating gene expression at the posttranscriptional level, and their expression and intracellular distribution are deregulated in many human diseases, including muscular dystrophies. Both in myotonic dystrophy type 1 and in myotonic dystrophy type 2 it has been demonstrated that the highly regulated pathways of miRNA are altered in skeletal muscle, potentially contributing to myotonic dystrophy pathogenetic mechanisms. A deregulation of microRNA in skeletal muscle and plasma from myotonic dystrophy type 2 patients has been also reported. The identification of minimally invasive analytical biomarkers for myotonic dystrophies and the established potential of circulating miRNAs as prognostic and diagnostic biomarkers are particularly important to monitor myotonic dystrophies progression and the effectiveness of new drug treatments.

A novel molecular mechanism that may contribute to the pathogenesis of myotonic dystrophies has been described by Zu and collaborators. RNA transcripts containing expanded CAG or CUG repeats can be translated in the absence of a starting ATG, and this noncanonical translation, called repeat associated non-ATG translation (RAN-translation), occurs across expanded repeats in all reading frames to produce potentially toxic homopolymeric proteins. It has been demonstrated that RAN-translation also occurs across transcripts containing the myotonic dystrophy type 2 CCUG or CAGG expansion mutation, producing tetra-repeat expansion proteins with a repeating Leu-Pro-Ala-Cys (LPAC) or Gln-Ala-Gly-Arg (QAGR) motif. Both LPAC and QAGR RAN proteins accumulate in myotonic dystrophy type 2 human autopsy brains in distinct patterns. For LPAC, cytoplasmic aggregates are found in neurons, astrocytes, and glia in the gray matter regions of the brain. In contrast, QAGR RAN protein accumulation, which is nuclear, is found primarily in oligodendrocytes located in white matter regions of the brain. Moreover, it has been evidenced that RAN protein accumulation can be modulated by MBNL1 levels and that nuclear sequestration of CCUG, CUG, or CAG RNAs decrease steady-state levels of RAN proteins. These data suggest that RAN-translation may be common to both myotonic dystrophy type 1 and type 2 and that RAN proteins may be responsible for some of the CNS features of myotonic dystrophies.

Table 1. Etiology of DM1 and DM2.

|                   | DM1          | DM2          |
|-------------------|--------------|--------------|
| Chromosomal locus | 19q 13.3     | 3q 21.3      |
| Gene              | DMPK         | ZNF9/CNBP    |
| Inheritance       | Autosomal dominant | Autosomal dominant |
| Mechanism         | CTG repeat expansion | CCTG repeat expansion |
| Normal repeat size| < 37         | < 27         |
| Pathologic repeat size | > 50     | > 75?        |
| Expanded repeat range | 50-4000 | 75-5000 -> 11000 |
| Anticipation      | Yes          | -----        |
expression of expanded CCUG repeats in a Drosophila model of myotonic dystrophy type 2.  

Several studies have revealed a role for CNBP in myotonic dystrophy type 2. CNBP deletion in several animal models results in severe brain and muscle phenotypes and other abnormalities similar to those seen in myotonic dystrophy type 2. These defects can be rescued by reintroduction of wild-type levels of CNBP, suggesting that a loss of CNBP function likely contributes to myotonic dystrophy type 2. Two reports using cell models describe a reduction of the rate of protein translation in myotonic dystrophy type 2 muscle cells due to a decrease of CNBP protein levels in myotonic dystrophy type 2 myoblasts and adult muscle and due to the interaction of CCUG repeats with cytoplasmic multiprotein complexes, which dysregulate translation and degradation of proteins in patients. Sammons and colleagues report that CNBP activity is reduced in myotonic dystrophy type 2 human myoblasts leading to a decrease in CNBP activation of IRES-mediated translation of the human ODC and suggest that CNBP activity may contribute to myotonic dystrophy type 2 phenotype. Moreover, the reduction of CNBP expression has been reported in myotonic dystrophy type 2 muscle biopsies but not in myotonic dystrophy type 1, thus explaining some of the phenotypic disparities between both types of myotonic dystrophies. Taken together, these data suggest that myotonic dystrophy type 2 pathology may be due to a combination of an RNA gain of function and CNBP loss of function.

The role of CUGBP1 in myotonic dystrophy type 2 is particularly intriguing, with contradictory results being reported. Cardani and colleagues demonstrated that this protein is overexpressed in muscle biopsies from patients affected by the adult classical form of myotonic dystrophy type 1 but not in muscle from myotonic dystrophy type 2 patients, suggesting that sequestration of MBNL1 evidently has a central role in splicing misregulation in both types of myotonic dystrophies, whereas CUGBP1 overexpression might be an additional pathogenic mechanism in myotonic dystrophy type 1 not shared by myotonic dystrophy type 2. However, it has been shown that MBNL1 overexpression in a mouse model of RNA toxicity (DM200) is not effective in reversing myotonic dystrophy type 1 phenotypes such as myotonia and cardiac conduction abnormalities. Also, the mice do not show improvement in function assays such as grip strength or treadmill running, and MBNL1 overexpression notably increases muscle histopathology and results in variable rescue of a number of splicing targets.

Vihola and collaborators investigated the molecular basis of muscle weakness and wasting and the differences in muscle phenotype between myotonic dystrophy type 1 and type 2. They identified differences in muscle gene expression and splicing between myotonic dystrophy type 1 and type 2 patients. In particular, the aberrant splicing isoform of TNNT3 is twice as frequent in myotonic dystrophy type 2 compared to myotonic dystrophy type 1. Moreover, in myotonic dystrophy type 1 and type 2, a different protein expression pattern has been found in the highly atrophic fibers. Concerning myotonic dystrophy type 2, skeletal muscle phenotype has been studied in heterozygous Cnbp KO mice and in human muscle samples. The study demonstrates that CNBP protein expression is reduced in cytoplasm of myotonic dystrophy type 2 muscle fibers, and it is predominantly localized at membrane level where its interaction with α-dystroglycan is increased compared to controls. These findings suggest that alterations of CNBP in myotonic dystrophy type 2 might cause muscle atrophy, not only via misregulation of mRNA but also via protein-protein interactions with membrane proteins affecting myofiber membrane function.

### Epidemiology

Myotonic dystrophy type 2 appears to have a lower prevalence than myotonic dystrophy type 1 and primarily affects populations with a Northern European heritage. For myotonic dystrophy type 2, there are currently no established prevalence estimates; myotonic dystrophy type 2 is generally thought to be rarer than myotonic dystrophy type 1, but large-scale population studies to confirm this have not been performed. In Germany, 267 mutation-verified molecular diagnoses were made between 2003 and 2005 compared with 277 myotonic dystrophy type 1 diagnoses within the same period. These data suggest that myotonic dystrophy type 2 appears to be more frequent than previously thought, with most myotonic dystrophy type 2 patients currently undiagnosed with symptoms frequently occurring in the elderly population. However, many patients in older generations with myotonic dystrophy type 1 or type 2 with milder symptoms are clearly undiagnosed. It is noteworthy that recessive mutations in the chloride channel gene CLCN1, which have a high frequency in the general population, can act as modifiers in patients with myotonic dystrophy type 2 disease by amplification of their myotonia. Meola’s group has identified myotonic dystrophy type 2 patients presenting an atypical phenotype characterized by early and severe myotonia without mutation on the CLCN1 gene but with mutations on SCN4A gene. Thus, both CLCN1 and SCN4A mutations may contribute to exaggerate the myotonia in myotonic dystrophy type 2.

### Clinical manifestation

There are no distinct clinical subgroups in DM2, and clinical presentation comprises a continuum ranging from...
early adult-onset severe forms to very late-onset mild forms that are difficult to differentiate from normal aging. Only 2 cases of neonatal forms have been reported so far in the literature: 1 of these patients had reduced intrauterine movements and muscle hypotonia after birth, and the second had only congenital talipes equinovarus without any other clinical sign. At present, there is no evidence of a congenital or childhood form of myotonic dystrophy type 2. The main difference in DM2 in comparison to DM1 is the absence of congenital form. Myotonic dystrophy type 2 typically presents in adulthood and has variable manifestations such as early onset cataracts (less than 50 years of age), various grip myotonias, thigh muscle stiffness, muscle pain, and weakness (in hip flexors, hip extensors, or long flexors of the fingers). These complaints often appear between 20 and 50 years of age. Posterior subscapular cataract before 50 years of age is a characteristic feature of myotonic dystrophy type 2, and early onset cataract can be a presenting feature of the disease, preceding all other symptoms. Pain is a common as well as a highly relevant problem for many patients with myotonic dystrophy type 2, with an estimated lifetime prevalence of 76% and a negative effect on quality of life. Patients and their care providers ascribe the symptoms to overuse of muscles, “pinched nerves”, “sciatica”, arthritis, or fibromyalgia. In comparison to other chronic muscle disorder patients, myotonic dystrophy type 2 patients more frequently describe a pain that is sometimes reported to be exercise-related, temperature-modulated, and palpation-induced (Tab. II). Younger patients may complain of stiffness or weakness when running up steps, whereas they infrequently complain of cramps. The muscle pain in myotonic dystrophy type 2 has no consistent relationship to exercise or to the severity of myotonia found on clinical examination. The pain, which tends to come and go without obvious cause, usually fluctuates in intensity and distribution over the limbs. It can last for days to weeks. This pain seems qualitatively different from the muscle and musculoskeletal pain that occurs in patients with myotonic dystrophy type 1. In a study on qualitative as well as quantitative aspects of pain in patients with myotonic dystrophy type 2, it has been observed that mechanical hyperalgesia is the main finding present in the rectus femoris, trapezius, and thenar, suggestive of at least a peripheral mechanism of pain. Pain appears to be most often located symmetrically in the proximal limbs. Myotonic dystrophy type 2 scored significantly lower than myotonic dystrophy type 1 on the bodily pain scale, indicating more body pain in myotonic dystrophy type 2. This finding has a high disease impact on physical as well as on mental health functioning, and on professional performance. A transcriptomic analysis performed on 12 muscle biopsy specimens obtained from myotonic dystrophy type 2 patients has identified 14 muscle genes significantly up- or down-regulated in myalgic patients compared to nonmyalgic myotonic dystro-
trophy type 2 patients. These data support the idea that molecular changes in the muscles of myotonic dystrophy type 2 patients are associated with muscle pain and suggest that muscle-specific molecular pathways might play a significant role in myalgia.73

Early in the presentation of myotonic dystrophy type 2, there is only mild weakness of hip extension, thigh flexion, and finger flexion. Myotonia of grip and thigh muscle stiffness varies from minimal to moderate severity over days to weeks. Direct percussion of forearm extensor and thenar muscles is the most sensitive clinical test for myotonia in myotonic dystrophy type 2. Myotonia may appear only on electromyographic testing after examination of several muscles.14,64 Facial weakness is mild in myotonic dystrophy type 2 as is muscle wasting in the face and limbs (Fig. 1). Weakness of neck flexors is frequent. Trouble arising from a squat is common, especially as the disease progresses (Fig. 2). Calf muscle hypertrophy occasionally is prominent (Fig. 3). Other manifestations, such as excessive sweating, hypogonadism, glucose intolerance, cardiac conduction disturbances, cognitive alterations, and neuropsychological alterations, may also occur and worsen over time.6,14,65,74 Sleep complaints and breathing disorders are also frequent in myotonic dystrophy type 2.75

A study on frequency and progression of cardiac and muscle involvement in a large cohort of patients with myotonic dystrophy type 2 demonstrated that the frequency and severity of cardiac involvement and muscle weakness are reduced in myotonic dystrophy type 2 compared to myotonic dystrophy type 1 and that progression is slower and less severe.76 Nevertheless, careful cardiac evaluation is recommended to identify patients at risk for potential cardiac major arrhythmia. A retrospective study comprised of 62 adult patients with myotonic dystrophy type 2 showed that cardiac conduction and rhythm defects are relatively rare in myotonic dystrophy type 2, although diastolic dysfunction is common, suggesting that regular ECG and echocardiography screening is needed in these patients.77 Cardiovascular magnetic resonance imaging (CMR) showed that cardiac involvement is more common in myotonic dystrophy type 2 than in myotonic dystrophy type 1.78

Figure 1. Mild atrophy, grade 4 MRC proximal muscle weakness in upper limbs in a patient affected by DM2.

Figure 2. Moderate atrophy and weakness of proximal lower limbs (grade 3 MRC) with difficulty in arising from a chair in a patient affected by DM2.

Figure 3. Calf hypertrophy in a patient affected by DM2.
demonstrates that in myotonic dystrophy type 2 patients subclinical myocardial injury was already detectable in preserved left ventricular ejection fraction. Moreover, extracellular volume was also increased in regions with no focal fibrosis and myocardial fibrosis was related to conduction abnormalities.

Patients with both myotonic dystrophy type 1 and type 2 have lower scores on frontal lobe functioning tests compared to controls and have an increased prevalence of avoidant personality disorders. In a study aimed to analyze personality patterns in a cohort of myotonic dystrophy type 1 and type 2 patients, no significant personality impairments have been observed in patients with myotonic dystrophy type 2, and the most common clinical symptoms observed in these patients were anxiety and somatization. In patients with type 2 disease, conventional brain MRI findings can be entirely normal. However, in advanced stages or more severe cases, diffuse white-matter changes can be present although be less pronounced than or different to that in myotonic dystrophy type 1. It has been reported that the main transcranial sonography finding in myotonic dystrophy type 2 patients is brainstem raphe hypoechogenicity, which is associated with fatigue and excessive daytime sleepiness. In addition, substantia nigra hyperechogenicity and increased diameter of the third ventricle has been observed. The type of cognitive impairment that occurs in myotonic dystrophy type 2 is similar to but less severe than that of myotonic dystrophy type 1. A specific type of “avoidant” personality and a significant impairment in frontal lobe function (especially limited ability to perform executive functions) have been observed in myotonic dystrophy type 1 and type 2 patients, although these abnormalities were milder in myotonic dystrophy type 2 patients. Similar observations have been reported in a study performed in a larger cohort of myotonic dystrophy type 2 patients. In conclusion there are clinical, neuropsychological, and neuroimaging data that support the hypothesis of central nervous system involvement also in myotonic dystrophy type 2.

Gastrointestinal manifestations are common in myotonic dystrophy type 2 patients, affecting their quality of life. A study on progression of gastrointestinal manifestations in these patients reports that during the 5 years of follow-up, the most common changes are the development of trouble swallowing and constipation and that female patients demonstrate a greater risk of a gastrointestinal manifestation. A relatively high frequency of cholecystectomy on average before 45 years of age is also reported.

It has been reported that hearing impairment is a frequent symptom in myotonic dystrophy type 2 patients and that the sensorineural hearing impairment is located in the cochlea. This suggests it is important to perform audiometry when hearing impairment is suspected in order to propose early hearing rehabilitation with hearing aids when indicated.

In a study conducted on a large cohort of 307 genetically-confirmed myotonic dystrophy type 2 patients, a profound gender and age influence on the phenotype has emerged, emphasizing that female gender and aging may be associated with a higher disease burden. Indeed, it appears that with aging, there is a tendency towards the worsening of weakness, whereas myalgia and myotonia tend to decrease. Females seem to be more severely affected than men as they show more frequently muscle weakness, multisystem involvement, and need of using walking aids. This study suggests that these age- and gender-specific differences should be considered in diagnostics, management, and future clinical studies of myotonic dystrophy type 2.

It has been observed that metabolic syndrome is common in myotonic dystrophy type 2 patients but not more frequent than in healthy subjects. However, treatment of metabolic disturbances may reduce cardiovascular complications and improve quality of life in patients with myotonic dystrophy type 2.

Body composition assessed by DEXA (dual-energy x-ray absorptiometry) reveals that patients with myotonic dystrophy type 1 and type 2 have similar total body mass, bone mineral content, fat mass, and lean tissue mass. Patients with myotonic dystrophy type 2 have less visceral fat deposition than those affected by myotonic dystrophy type 1. Also, right rib bone mineral density was lower in myotonic dystrophy type 2 patients.

Overall the prognosis for patients with myotonic dystrophy type 2 is more favorable than for individuals with myotonic dystrophy type 1. Patients usually have a slower, less severe, and less widespread progression of muscle weakness and less muscle wasting. Does not seem to be a more severe phenotype associated with the homozygotic form of this disease. As in myotonic dystrophy type 1, patients with myotonic dystrophy type 2 who have an earlier onset of symptoms have an earlier onset of myotonia and weakness. The natural history of myotonic dystrophy type 2 remains to be fully defined, but present information indicates that most patients have a normal lifespan. Respiratory failure, hypersomnia, and recurrent aspiration or pneumonia are not common in myotonic dystrophy type 2. Cardiac conduction disturbances occur, but they are less frequent compared to myotonic dystrophy type 1. An investigation using a variety of standard tests of autonomic function (response to Valsalva maneuver, deep breathing, change in posture, grip, analysis of heart rate variability) reveals no major abnormalities in patients with myotonic dystrophy type 2.
Diagnosis

The gold standard for establishing the diagnosis of myotonic dystrophy type 2/proximal myotonic myopathy is to demonstrate the presence of abnormal CCTG repeats in the 3q21 zinc finger protein 9 (ZNF9/CNBP) gene involved with myotonic dystrophy type 2.

Leucocyte DNA testing is also available for myotonic dystrophy type 2, but previous DNA analysis for diagnosing myotonic dystrophy type 2 and proximal myotonic myopathy may have missed as many as 20% of affected individuals. As for myotonic dystrophy type 1, a new ready to use genetic test has been validated to identify the myotonic dystrophy type 2 disease, with the advantage to reduce errors that can be introduced using homemade reagents. However, the myotonic dystrophy type 2 diagnostic odyssey is complicated by the difficulties to develop an accurate, robust, and cost-effective method for a routine molecular assay.

A more practical tool for myotonic dystrophy type 2 diagnosis than the complex genotyping procedure is via in situ hybridization detection of nuclear accumulations of CCUG-containing RNA in myotonic dystrophy type 2 muscle biopsy using specific probes. Moreover, because MBNL1 is sequestered by mutant RNA foci, it is possible to visualize the nuclear accumulation of MBNL1 by immunofluorescence on muscle sections. However, although MBNL1 represents a histopathological marker of myotonic dystrophies, it does not allow one to distinguish between myotonic dystrophy type 1 and myotonic dystrophy type 2. Another tool to investigate muscle weakness and wasting is muscle imaging with MRI. In type 2 disease, early muscular changes develop in the anterior vastus group of thigh muscles, with relative sparing of the rectus femoris. The main aspects of multisystemic involvement are summarized in the Table II.

Management

In general, the management of myotonic dystrophy type 2 is similar to myotonic dystrophy type 1, but there is less need for supportive care like bracing, scooters, or wheelchairs. Cataracts require monitoring, and serial monitoring of ECG is necessary to check for covert arrhythmia. Disturbances in cardiac rhythm are less frequent in myotonic dystrophy type 2, but abnormalities do occur. Hypogonadism and insulin resistance need monitoring as in myotonic dystrophy type 1. Myotonia tends to be less marked and less troublesome in myotonic dystrophy type 2, but in specific circumstances, especially if muscle stiffness is frequent and persistent, anti-myotonia therapy with mexiletine is helpful. Cognitive difficulties also occur in myotonic dystrophy type 2, as in myotonic dystrophy type 1, and appear to be associated with decreased cerebral blood flow to frontal and anterior temporal lobes and decreased brain volume. The changes are less severe than in myotonic dystrophy type 1. Their etiology is unknown but may relate to the toxic effect of intranuclear accumulations of abnormally expanded RNA. Management of these brain symptoms is similar to that for myotonic dystrophy type 1.

A frequent and difficult problem in myotonic dystrophy type 2 is the peculiar muscle pain described earlier. The exact mechanism underlying the pain is unknown, and there is no well-established effective treatment. Carbamazepine or mexiletine along with nonsteroidal anti-inflammatory medications ameliorate this pain in some patients. However, others with severe pain may require opiates on a regular basis to obtain relief. Fortunately, this peculiar muscle pain is not typical in myotonic dystrophy type 1. Guidelines on diagnosis and management have been published. Care considerations and management issues on the wide spectrum of disease manifestations in DM2 have been published recently by a Consortium of international Experts.

For pregnancy and anesthesia there are some special considerations.

Pregnancy

Studies of prenatal diagnosis using sensitive DNA testing for myotonic dystrophy type 2 myopathy are theoretically possible and more information is likely to become available in near future. If a mother has myotonic dystrophy type 2 with only minimal symptoms at the time of her pregnancy, she may have an increased risk of developing myotonia and weakness in the later stages of the pregnancy. In 1 study of 96 pregnancies in 42 myotonic dystrophy type 2 women, it was found that 21% of the women had their first myotonic symptoms during their pregnancy. Additionally, 17% of their pregnancies ended in miscarriages, and 27% ended in preterm labor. Two reports suggest that the symptoms that develop during pregnancy reverse after delivery, but more information is necessary to make such a prediction with certainty.

Anesthesia

One study of a large number of individuals with myotonic dystrophy type 2 has found no significant problems with the ability of patients to tolerate general anesthesia. In a report of a large German patient cohort, the overall frequency of severe complications was 0.6% (2 of 340). The overall lower risk seems to be predominantly related to the minor respiratory involvement in myotonic dystrophy type 2 than in myotonic dystrophy type 1.
Conclusions

Twenty-eight years have passed since the (CTG)n repeat expansion mutation was discovered in patients with myotonic dystrophy type 1, and 19 years ago the (CCTG)n mutation was identified in type 2 disease. Emerging data indicate that molecular pathomechanisms are much more complex than could have been envisioned when the respective mutations were just identified. RNA toxicity clearly has a major role, yet spliceopathy alone does not seem to fully account for all aspects of the multisystemic phenotype in myotonic dystrophies. Other pathomechanisms consistent with the toxic RNA model probably entail regulation of gene expression and translation and various cellular stress pathways and extend beyond the nucleus to the cytoplasm. Nevertheless, it is important to emphasize that despite clinical and genetic similarities, myotonic dystrophy type 1 and type 2 are distinct disorders requiring different diagnostic and management strategies.

Although treatment of myotonic dystrophy type 1 and myotonic dystrophy type 2 is currently limited to supportive therapies, new therapeutic approaches based on pathogenic mechanisms may become feasible in near future.

The future holds great promise for advances in translational research in DM2. The teamwork will expedite the development of targeted therapies and improve the lives of patients and their families.

Acknowledgments

This study was mainly supported by grants from Fondazione Malattie Miotoniche-FMM, Milan, Italy.

References

1. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member. Cell 1992;68:799-808. https://doi.org/10.1016/0092-8674(92)90154-5
2. Fu YH, Pizzuti A, Fenwick RG Jr, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992;255:1256-8. https://doi.org/10.1126/science.1546326
3. Mahadevan M, Tsiflidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3’ untranslated region of the gene. Science 1992;255:1253-5. https://doi.org/10.1126/science.1546325
4. Thornton CA, Griggs RC, Moxley RT 3rd. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 1994;35:269-72. https://doi.org/10.1002/ana.410350305
5. Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994;44:1448-52. https://doi.org/10.1212/wnl.44.8.1448
6. Meola G, Sansone V, Radice S, et al. A family with an unusual myotonic and myopathic phenotype and no CTG expansion (proximal myotonic myopathy syndrome): a challenge for future molecular studies. Neuromuscul Disord 1996;6:143-50. https://doi.org/10.1016/0960-8966(95)00040-2
7. Udd B, Krahe R, Wallgren-Pettersson C, et al. Proximal myotonic dystrophy – a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes. Neuromuscul Disord 1997;217-28. https://doi.org/10.1016/s0960-8966(97)00041-2
8. Ranum LP, Rasmussen PF, Benzow KA, et al. Genetic mapping of a second myotonic dystrophy locus. Nature Genetics 1998;19:196-8. https://doi.org/10.1038/570
9. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293:864-7. https://doi.org/10.1126/science.1062125
10. Valaperta R, Sansone V, Lombardi F, et al. Identification and characterization of DMI patients by a new diagnostic certified assay: neuromuscular and cardiac assessments. Biomed Res Int 2013;2013:958510. https://doi.org/10.1155/2013/958510
11. Bachinski LL, Udd B, Meola G, et al. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet 2003;73:835-48. https://doi.org/10.1086/378566
12. Schozer BG, Kress W, Walter MC, et al. Homozygosity for CCTG mutation in myotonic dystrophy type 2: human founder haplotype and evolutionary conservation of the repeat tract. Am J Hum Genet 2003;73:849-62. https://doi.org/10.1086/378720
13. Bachinski LL, Czernuszewicz T, Ramagli LS, et al. Premutation allele pool in myotonic dystrophy type 2. Neurology 2003;60:657-64. https://doi.org/10.1212/01.wnl.0000054481.84978.9f
14. Day JW, Ricker K, Jacobsen JF, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003;60:657-64. https://doi.org/10.1212/01.wnl.0000054481.84978.9f
15. Ranum LP, Day JW. Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2. Curr Neurol Neurosci Rep 2002;2:465-70. https://doi.org/10.1007/s11910-002-0074-6
16. Timchenko LT, Tapscott SJ, Cooper TA, et al. Myotonic dystrophy:
20 Mankodi A, Teng-Umnuay P, Krym M, et al. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol 2003;54:760-8. https://doi.org/10.1002/ana.10763

21 Cardani R, Mancinelli E, Sansone V, et al. Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy. Eur J Histochim 2004;48:437-42. https://doi.org/10.4081/918

22 Jones K, Wei C, Schoser B, et al. Reduction of toxic RNAs in myotonic dystrophies type 1 and type 2 by the RNA helicase p68/DDX5. Proc Natl Acad Sci U S A 2015;112:8041-5. https://doi.org/10.1073/pnas.1422731112

23 Tapscott SJ, Thornton CA. Biomedicine. Reconstructing myotonic dystrophy. Science 2001;293:816-7. https://doi.org/10.1126/science.1063517

24 Day JW, Ranum LP. RNA phatogenesis of the myotonic dystrophy type 1/type 2 differences. Nat Commun 2018;9:2009. https://doi.org/10.1038/s41467-018-04370-x

25 Fakan S. Perichromatin fibrils are in situ forms of nascent transcripts. Trend Cell Biol 1994;4:86-90. https://doi.org/10.1016/0962-8924(94)90180-5

26 Perdoni F, Malatesta M, Cardani R, et al. RNA/MBNL1-containing foci in myoblast nuclei from patients affected by myotonic dystrophy type 2: an immunocytochemical study. Eur J Histochim 2009;53:151-8. https://doi.org/10.4081/ejh.2009.151

27 Osborne RJ, Thornton CA. RNA-dominant diseases. Hum Mol Genet 2006;15:162-9. https://doi.org/10.1093/hmg/ddl181

28 Meola G, Cardani R. Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Biochim Biophys Acta 2015;1852:594-606. https://doi.org/10.1016/j.bbadis.2014.05.019

29 Renna LV, Bosè F, Iachettini S, et al. Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 skeletal muscle. PLoS One 2017;12:e0184987. https://doi.org/10.1371/journal.pone.0184987

30 Renna LV, Bosè F, Brigonzi E, et al. Aberrant insulin receptor expression is associated with insulin resistance and skeletal muscle atrophy in myotonic dystrophies. PLoS One 2019;14:e0214254. https://doi.org/10.1371/journal.pone.0214254

31 Sznajder ŁJ, Swanson MS. Short tandem repeat expansions and RNA-mediated pathogenesis in myotonic dystrophy. Int J Mol Sci 2019;20:E3365. https://doi.org/10.3390/ijms20133365

32 Eisenberg I, Alexander MS, Kunkel LM. miRNAs in normal and diseased skeletal muscle. J Cell Mol Med 2009;13:2-11. https://doi.org/10.1111/j.1582-4934.2008.00524.x

33 Greco S, De Simone M, Colussi C, et al. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J 2009;23:3335-46. https://doi.org/10.1096/fj.08-128579

34 Gambardella S, Rinaldi F, Lepore SM, et al. Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients. J Transl Med 2010;8:48. https://doi.org/10.1186/1479-5876-8-48

35 Perbellini R, Greco S, Sarra-Ferraris G, et al. Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul Disord 2011;21:81-8. https://doi.org/10.1016/j.nmd.2010.11.012

36 Greco S, Perfetti A, Fasanaro P, et al. Deregulated microRNAs in myotonic dystrophy type 2. PLoS One 2012;7:e39732. https://doi.org/10.1371/journal.pone.0039732

37 Perfetti A, Greco S, Cardani R, et al. Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1. Sci Rep 2016;6:38174. https://doi.org/10.1038/srep38174

38 Zu T, Gibbens B, Doty NS, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A 2011;108:260-5. https://doi.org/10.1073/pnas.1013343108

39 Pearson CE. Repeat associated non-ATG translation initiation: one DNA, two transcripts, seven reading frames, potentially nine toxic entities! PLoS Genet 2011;7:e1002018. https://doi.org/10.1371/journal.pgen.1002018

40 Zu T, Cleary JD, Liu Y, et al. RAN translation regulated by Muscleblind proteins in myotonic dystrophy type 2. Neuron 2017;95:1292-305. https://doi.org/10.1016/j.neuron.2017.08.039

41 Sellier C, Cerro-Herreros E, Blatter M, et al. rIF0X1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences. Nat Commun 2018;9:2009. https://doi.org/10.1038/s41467-018-04370-x

42 Chen W, Liang Y, Deng W, et al. The zinc-finger protein CNBP is required for forebrain formation in the mouse. Development 2003;130:1367-79. https://doi.org/10.1242/dev.00349

43 Abe Y, Chen W, Huang W, et al. CNBP regulates forebrain formation at organogenesis stage in chick embryos. Dev Biol 2006;295:116-27. https://doi.org/10.1016/j.ydbio.2006.03.012

44 Chen W, Wang Y, Abe Y, et al. Haploinsufficiency for Znf9 in Znf9+/2 mice is associated with multiorgan abnormalities resembling myotonic dystrophy. J Mol Biol 2007;368:8-17. https://doi.org/10.1016/j.jmb.2007.01.088

45 Weiner AM, Allende ML, Becker TS, et al. CNBP mediates neural crest cell expansion by controlling cell proliferation and cell survival during rostral head development. J Cell Biochem 2007;102:1553-27. https://doi.org/10.1002/jcb.21380

46 Huichalaf C, Schoser B, Schneider-Gold C, et al. Reduction of the rate of protein translation in patients with myotonic dystrophy 2. J Neurosci 2009;29:9042-9. https://doi.org/10.1523/JNEUROSCI.1983-09.2009

47 Salisbury E, Schoser B, Schneider-Gold C, et al. Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in myotonic dystrophy 2 patients. Am J Pathol 2009;175:748-62. https://doi.org/10.2353/ajpath.2009.090047

48 Sammons MA, Antons AK, Bendjennat M, et al. ZNF9 activation
of IRES-mediated translation of the human ODC mRNA is decreased in myotonic dystrophy type 2. PLoS One 2010;5:e9301. https://doi.org/10.1371/journal.pone.0009301

Cardani R, Bugiardini E, Renna LV, et al. Overexpression of CUGBP1 in skeletal muscle from adult classic myotonic dystrophy type 1 but not from myotonic dystrophy type 2. PLoS One 2013;8:e3777. https://doi.org/10.1371/journal.pone.0083777

Lin X, Miller JW, Mankodi A, et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 2006;15:2087-97. https://doi.org/10.1093/hmg/ddl132

Pelletier R, Hamel F, Beaulieu D, et al. Absence of a differentiation defect in muscle satellite cells from DM2 patients. Neuromuscul Disord 2009;19:181-90. https://doi.org/10.1016/j.nmd.2009.07.009

Yadava RS, Kim YK, Mandal M, et al. MBNL1 overexpression is not sufficient to rescue the phenotypes in a mouse model of RNA toxicity. Hum Mol Genet 2019;28:2330-8. https://doi.org/10.1093/hmg/ddz065

Vihola A, Bachinski LL, Sirito M, et al. Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2. Acta Neuropathol 2010;119:465-79. https://doi.org/10.1007/s00401-010-0637-6

Wei C, Stock L, Schneider-Gold C, et al. Reduction of cellular nucleic acid binding protein encoded by a myotonic dystrophy type 2 gene causes muscle atrophy. Mol Cell Biol 2018;38:e00649-17. https://doi.org/10.1128/MCB.00649-17

Suominen T, Bachinski LL, Auvinen S, et al. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet 2011;19:776-82. https://doi.org/10.1038/ejhg.2011.23

Suominen T, Schoser B, Raheem O, et al. High frequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany. J Neurol 2008;255:1731-6. https://doi.org/10.1007/s00415-008-0010-z

Cardani R, Giagnacovo M, Botta A, et al. Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2. J Neurol 2012;2090-9. https://doi.org/10.1007/s00415-012-6462-1

Peddarreddygari LR, Grewal AS, Grewal RP. Focal seizures in a patient with myotonic dystrophy type 2 co-segregating with a chloride voltage-gated channel 1 gene mutation: a case report. J Med Case Rep 2016;10:167. https://doi.org/10.1186/s13256-016-0958-8

Bugiardini E, Rivolta I, Binda A, et al. SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype. Neuromuscul Disord 2015;25:301-7. https://doi.org/10.1016/j.nmd.2015.01.006

Meola G, Cardani R. Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects. Neurol Sci 2017;38:535-46. https://doi.org/10.1007/s10072-016-2805-5

Binda A, Renna LV, Bosé F, et al. SCN4A as modifier gene in patients with myotonic dystrophy type 2. Sci Rep 2018;8:11058. https://doi.org/10.1038/s41598-018-29302-z

Kruse B, Wöhle D, Steinbach P, et al. Does proximal myotonic myopathy show anticipation. Hum Mutat 2008;29:e100-2. https://doi.org/10.1002/humu.20791

Renard D, Rivier F, Dimeglio A, et al. Congenital talipes equinovarus associated with myotonic dystrophy type 2. Muscle Nerve 2010;42:457. https://doi.org/10.1002/mus.21738

Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic myopathy. Clinical features of a multisystem disorder similar to myotonic dystrophy. Arch Neurol 1995;52:25-31. https://doi.org/10.1001/archneur.1995.00540250029009

Day JW, Roelofs R, Leroy B, et al. Clinical and genetic characteristics of a five-generation family with a novel form of myotonic dystrophy (DM2). Neuromuscul Disord 1999;9:19-27. https://doi.org/10.1016/s0960-8966(98)00094-7

Meola G. Clinical and genetic heterogeneity in myotonic dystrophies. Muscle Nerve 2000;23:1789-99. https://doi.org/10.1010/s00412-000-0202-8

Moxley RT 3rd, Meola G, Udd B, et al. Report of the 84th ENMC workshop: PROMM (proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13-15th October 2000. Loosdrecht, The Netherlands. Neuromuscul Disord 2002;12:306-17. https://doi.org/10.1016/s0960-8966(01)00284-x

Papadopoulos C, Kekou K, Xirou S, et al. Early onset posterior subcapsular cataract in a series of myotonic dystrophy type 2 patients. Eye (Lond) 2018;32:622-25. https://doi.org/10.1038/eye.2017.280

van Vliet J, Tieleman AA, Verrips A, et al. Qualitative and quantitative aspects of pain in patients with myotonic dystrophy type 2. J Pain 2018b;19:920-30. https://doi.org/10.1016/j.jpain.2018.03.006

George A, Schneider-Gold C, Zier S, et al. Musculoskeletal pain in patients with myotonic dystrophy type 2. Arch Neurol 2004;61:1938-42. https://doi.org/10.1001/archneur.61.12.1938

Tieleman AA, Knoop H, van de Logt AE, et al. Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2. J Neurol Neurosurg Psychiatry 2010;81:963-7. https://doi.org/10.1136/jnnp.2009.192591

Suokas KI, Haanpää M, Kautiainen H, et al. Pain in patients with myotonic dystrophy type 2: a postal survey in Finland. Muscle Nerve 2012;45:70-4. https://doi.org/10.1002/mus.22249

Moshourab R, Palada V, Grunwald S, et al. A molecular signature of myalgia in myotonic dystrophy 2. EBioMedicine 2016;7:205-11. https://doi.org/10.1016/j.ebiom.2016.03.017

Meola G, Sansone V, Perani D, et al. Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy. Neurology 1999;5:1042-50. https://doi.org/10.1212/wnl.53.5.1042

Romigi A, Maestri M, Nicoletta C, et al. Sleep complaints, sleep and breathing disorders in myotonic dystrophy type 2. Curr Neurol Neurosci Rep 2019;19:9. https://doi.org/10.1007/s11910-019-0924-0
Mariana F, Mondello S, Wenninger S, et al. Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2. J Neurol 2017;264:2472-80. https://doi.org/10.1007/s00415-017-8653-2

Peric S, Bjelica B, Alekovic K, et al. Heart involvement in patients with myotonic dystrophy type 2. Acta Neurol Belg 2019a;119:77-82. https://doi.org/10.1007/s13760-018-1052-3

Schmacht L, Traber J, Grieben U, et al. Cardiac involvement in myotonic dystrophy Type 2 Patients with preserved ejection fraction: detection by cardiovascular magnetic resonance. Circ Cardiovasc Imaging 2016;9:e004615. https://doi.org/10.1161/CIRCIMAGING.115.004615

Punic T, Peric S, Parojcic A, et al. Personality traits in patients with myotonic dystrophy type 2. Acta Myol 2017;36:14-8. PMID 28690389

Romeo V, Pegoraro E, Ferrati C, et al. Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2. J Neurol 2010;257:1246-55. https://doi.org/10.1007/s00415-010-5498-3

Minnerop M, Weber B, Schoene-Bake JC, et al. The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease. Brain 2011;134(pt 12):3530-46. https://doi.org/10.1093/brain/awr299

Rakovecic-Stojanovic V, Peric S, Savic-Pavicevic D, et al. Brain sonography insight into the midbrain in myotonic dystrophy type 2. Muscle Nerve 2016;53:700-4. https://doi.org/10.1002/mus.24927

Meola G, Sansone V, Perani D, et al. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM1) and in proximal myotonic myopathy (DM2/PROMM). Neuro muscular Disord 2003;13:813-21. https://doi.org/10.1016/s0960-8966(03)00137-8

Peric S, Mandic-Stojmenovic G, Stefanova E, et al. Frontostraltriatal dysexecutive syndrome: a core cognitive feature of myotonic dystrophy type 2. J Neurol 2015;262:142-8. https://doi.org/10.1007/s00415-017-8653-2

Meola G, Sansone V, Marinou K, et al. Proximal myotonic myopathy: a syndrome with a favourable prognosis. J Neurol Sci 2002;193:89-96. https://doi.org/10.1016/s0022-510x(01)00649-9

Schoser BG, Ricker K, Schneider-Gold C, et al. Sudden cardiac death in myotonic dystrophy type 2. Neurology 2004b;63:2402-4. https://doi.org/10.1212/01.wnl.0000147335.10783.e4

Flachenecker P, Schneider C, Cursiefen S, et al. Assessment of cardiovascular autonomic function in myotonic dystrophy type 2 (DM2/PROMM). Neuromuscul Disord 2003;13:289-93. https://doi.org/10.1016/s0960-8966(02)00277-8

Valaperta R, Lombardi F, Cardani R, et al. Development and validation of a new molecular diagnostic assay for detection of myotonic dystrophy type 2. Genet Test Mol Biomarkers 2015;19:703-9. https://doi.org/10.1089/gtmb.2015.0135

Sallinen R, Vihola A, Bachinski LL, et al. New methods for molecular diagnosis and demonstration of the (CCTG)n mutation in myotonic dystrophy type 2 (DM2). Neuromuscul Disord 2004;14:274-83. PMID 15019706

Cardani R, Mancinelli E, Rotondo G, et al. Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2. Eur J Histochem 2006;50:177-82. PMID 16920640

Udd B, Meola G, Krahe R, et al. Proximal myotonic dystrophy type 2 (DM2) and related disorders report of the 180th ENMC workshop including guidelines on diagnostics and management 3-5 December 2010, Naarden, The Netherlands. Neuromuscul Disord 2011;21:443-50. https://doi.org/10.1016/j.nmd.2011.03.013

Chang L, Ernst T, Osborn D, et al. Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats. Arch Neurol 1998;55:305-11. https://doi.org/10.1001/archneur.55.3.305

Akiyuchi I, Nakano S, Shino A, et al. Brain proton magnetic resonance spectroscopy and brain atrophy in myotonic dystrophy. Arch Neurol 1999;56:325-30. https://doi.org/10.1001/archneur.56.3.325

Schoser BG, Montagnese F, Bassez G, et al. Consensus-based care recommendations for adults with myotonic dystrophy type 2. Neurol Clin Pract 2019;9:343-53. https://doi.org/10.1212/CNPJ.0000000000000645

Newman B, Meola G, O’Donovan DG, et al. Proximal myotonic myopathy (PROMM) presenting as myotonia during pregnancy. Neuromuscular Disord 1999;3:144-9. https://doi.org/10.1016/s0960-8966(98)00118-7
Rudnik-Schoneborn S, Schneider-Gold C, Raabe U, et al. Outcome and effect of pregnancy in myotonic dystrophy type 2. Neurology 2006;66:579-80. https://doi.org/10.1212/01.wnl.0000198227.91131.1e

Kirzinger L, Schmidt A, Kornblum C, et al. Side effects of anesthesia in DM2 as compared to DM1: a comparative retrospective study. Eur J Neurol 2010;17:842-5. https://doi.org/10.1111/j.1468-1331.2009.02942.x

Moxley RT, Hilbert JE, Meola G. The myotonic dystrophies. In: Rosenberg RN, Pascual JM, Eds. Rosenberg’s molecular and genetic basis of neurological and psychiatric disease. 6th edition. Vol. 2, San Diego (CA): Elsevier 2020.